KROS
Keros Therapeutics
$10.21
+$0.15 (+1.49%)Jul 27, 2026
Key metrics
The numbers that frame KROS today
- Market cap
- $202.07M
- P/E (TTM)
- -2.4
- EV / FCF
- 1.1
- Gross margin
- 100%
- EV / Sales
- -1.9
- ROIC
- -214.5%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $9.69
- 52wk High
- $22.55
Growth
Revenue and earnings trend for KROS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about KROS
Is Keros Therapeutics a good buy?
No. Keros Therapeutics has strong quality, but poor momentum undercuts the setup. Growth looks poor. That could put pressure on the long-term business case.
What is the market capitalization of KROS?
Keros Therapeutics's market capitalization is $202.07M.
What is the P/E ratio for KROS stock?
Keros Therapeutics's current P/E ratio is -2.4.
What is the 52-week high for KROS stock?
The 52-week high for Keros Therapeutics is $22.55. The current close of $10.21 is 54.7% below that high.
What is the 52-week low for KROS stock?
The 52-week low for Keros Therapeutics is $9.69. The current close of $10.21 is 5.4% above that low.
Does KROS stock pay dividends?
Keros Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for KROS?
Keros Therapeutics's Debt / Equity ratio is 0.06.